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Abstract  
Background and Aims: The transcription factors Foxf1 and Foxf2 have been 
implicated in the development of the gastrointestinal tract but their role in adults or in 
gastrointestinal diseases is poorly understood. We have recently shown that expression 
of serum response factor (SRF), a transcription factor whose activity is modulated by 
Foxf proteins, is decreased in the stomach muscularis of patients with gastroparesis. 
The aim of the current study was to determine if FOXF expression is decreased in 
gastroparesis patients and if loss of Foxf1 and/or Foxf2 from adult smooth muscle is 
sufficient to impair gastric emptying in mice. Methods: Full thickness stomach biopsy 
samples were collected from control subjects and from patients with gastroparesis. 
mRNA was isolated from the muscularis externa and FOXF mRNA expression levels 
were determined by quantitative reverse transcriptase (RT)-PCR. Foxf1 and Foxf2 were 
knocked out together and separately from smooth muscle cells in adult mice and the 
subsequent effect on liquid gastric emptying and contractile protein expression were 
determined. Key Results: Expression of FOXF1 and FOXF2 is decreased in smooth 
muscle tissue from gastroparesis patients. Knockout of Foxf1 and Foxf2 together, but 
not alone, from mouse smooth muscle resulted in delayed liquid gastric emptying.  
Foxf1/2 double knockout mice had decreased expression of smooth muscle contractile 
proteins, SRF and myocardin in stomach muscularis. Conclusions and Inferences: 
Our findings suggest that decreased expression of Foxf1 and Foxf2 may be contributing 
to the impaired gastric emptying seen in gastroparesis patients.  
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Key Points 
• Gastroparesis is a debilitating disease with complex etiology including altered 
transcription regulation in gastric smooth muscle. We aimed to determine the role 
of forkhead transcription factors in gastric smooth muscle in the pathology of 
gastroparesis. 
• Forkhead transcription factors FOXF1 and FOXF2 are decreased in smooth 
muscle tissue from gastroparesis patients and knockout of Foxf1 and Foxf2 
together, but not alone, from mouse smooth muscle resulted in delayed liquid 
gastric emptying associated with decreased expression of smooth muscle 
contractile proteins. 
• Our findings suggest that FOXF1 and FOXF2 are required for the normal function 
of the stomach and that loss of these proteins may contribute to the development 
of gastroparesis. 
 
 
Abbreviations: 
ICC- Interstitial Cells of Cajal 
GI- gastrointestinal 
PDGFRα+ fibroblasts- Platelet derived growth factor receptor alpha positive fibroblasts 
SMCs- smooth muscle cells 
SRF- serum response factor 
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Gastroparesis defined as delayed gastric emptying in the absence of a physical 
obstruction, is estimated to occur in about 1.8% of the adult population, with the majority 
of cases being in women.1,2 Symptoms of gastroparesis can be debilitating, dramatically 
lowering quality of life.3 Overall, gastrointestinal motility and functional bowel disorders 
cause a huge burden on the US healthcare system.4,5 Etiologies of gastroparesis are 
approximately 36% idiopathic (unknown etiology), 29% diabetic and 13% 
postsurgical.6,7 Gastric emptying is dependent on an intricate interaction of neural cells, 
interstitial cells of Cajal (ICC), platelet derived growth factor α positive (PDGFRα+) 
fibroblasts and smooth muscle cells (SMCs). 8-12 ICC are the pacemaker cells in the 
stomach that transmit slow wave depolarization to the gastric smooth muscle cells.10,13 
The PDGFRα+ fibroblasts are a more recently recognized component of the electrical 
syncytium that controls gastric contractility. These cells transmit inhibitory neural signals 
to gastric smooth muscle cells.8 It is likely that defects in any of these cell types could 
impair gastric emptying resulting in gastroparesis. 
 
Histopathological analyses have suggested decreases in numbers of ICCs and 
increases in numbers of CD45 and CD68 positive cells in gastric full-thickness biopsies 
from diabetic and idiopathic gastroparesis patients.14 In contrast, it has been reported 
that there are no changes in the PDGFRα+ cell number in either group of gastroparesis 
patients.9 It has also been proposed that an increased ratio of M1 relative to M2 
macrophages may contribute to delayed gastric emptying in diabetic gastroparesis.15 
We have recently challenged some of these findings using qRT-PCR analysis of RNA 
isolated from the stomach muscularis of control and gastroparesis patients. We found 
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that idiopathic gastroparesis is associated with decreased mRNA encoding smooth 
muscle cell contractile proteins and PDGFRα+ without a change in mRNA encoding ICC 
markers.16 The altered expression of mRNA encoding contractile proteins was 
correlated with decreased expression of serum response factor (SRF) a transcription 
factor that is crucial for regulating the differentiation state of smooth muscle cells.17 
Knockout of SRF from adult smooth muscle cells has been show to impair intestinal 
motility resulting in pseudo-obstruction.18,19 SRF can promote the proliferation, migration 
or differentiation of smooth muscle cells depending on which other transcription factors 
and co-regulators that it interacts with.20 One critical co-regulator that promotes SRF’s 
myogenic activity is myocardin. 21 During the biphasic remodeling that occurs in the 
intestine following partial obstruction, the proliferative phase is associated with 
decreased expression of myocardin and SRF and decreased binding of SRF to the 
promoters of smooth muscle contractile protein genes.22 In contrast, in the hypertrophic 
phase myocardin expression is increased and more SRF is found at the promoters of 
contractile protein genes.22  
 
We have previously shown that the transcription factors Foxf1 and Foxf2 also interact 
with SRF and myocardin to regulate transcriptional activity within gastrointestinal 
smooth muscle cells.23,24 Loss of Foxf1 from smooth muscle cells during embryonic 
development resulted in early postnatal lethality that was associated with severe 
abnormalities in the gastrointestinal tract, including markedly dilated esophagus and 
stomach.24 In contrast, loss of Foxf2 from smooth muscle cells during embryonic 
 Herring       6 
development resulted in an expansion of the myenteric nerve plexus that may have 
been associated with increased expression of PDGFb.23  
 
Given the known roles of Foxf, myocardin and SRF complexes in regulating the 
phenotype of smooth muscle cells and our previous findings of altered expression of 
mRNAs encoding some smooth muscle contractile proteins in gastric muscle of patients 
with gastroparesis, we set out to determine the potential roles of the Foxf proteins in 
regulating gastric emptying and contributing to the pathology of gastroparesis. 
 
Materials and Methods 
Clinical assessment and human full-thickness stomach biopsies. This study received 
IRB approval  from the Indiana University Institutional Review Board (protocol 
#1309147354R004). Biopsies from the control group of human subjects were obtained 
from either non-diabetic or diabetic individuals without gastroparesis symptoms that 
were undergoing bariatric weight loss surgery as described previously (normal HbA1c 
level < 1 month prior to surgery in non-diabetic group)16. Control and gastroparesis 
subjects were age and sex matched. The average ages of the non-diabetic control and 
gastroparesis patients were 42.8±7.8 years and 34.6±10.1 years, respectively, with 11 
of 14 (79%) control subjects being female compared to 14 out of 16 (87%) patients with 
gastroparesis. The average ages of the diabetic control and gastroparesis patients were 
52.1±12.1 years and 40.9±10.5 years, respectively with 78% of the diabetic control 
patients and 82% of the diabetic gastroparesis patients being female. Gastroparesis 
was defined as patients with symptoms of gastroparesis ≥ 3 months with delayed 
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gastric emptying by 4-hour gastric scintigraphy or gastric bezoar with undigested foods 
by upper endoscopy after an overnight fast. Gastric scintigraphy was performed 
following consumption of a low fat egg-white meal with imaging at 0, 2 and 4hrs as 
described previously.25,26 Abnormal gastric emptying was defined as 2-hour retention 
≥60% or 4-hour retention ≥10%. 
 
Surgical full-thickness biopsies from the gastroparesis patients were obtained at the 
time of routine pathological analysis in patients with severe idiopathic gastroparesis or 
at the time of gastric stimulator placement. In each case (control and gastroparesis 
patients), the biopsy was taken about 10cm from the pylorus on the anterior aspect 
midway between the greater and lesser curvatures of the stomach. All laproscopic 
biopsies were obtained using linear cutting staplers. For sleeve gastrectomy subjects 
the sample was obtained after the stomach was removed from the abdomen. Tissues 
were collected into ice cold DMEM (Dullbeco’s modified eagle media) or RNAlater 
(Ambion) and immediately transferred to the investigator’s laboratory. Muscle, 
submucosal and mucosal layers were separated by dissection, flash frozen in liquid 
nitrogen and ground to a powder under liquid nitrogen prior to storage at -80°. A small 
amount of frozen muscle tissue powder (~150mg) was homogenized in Trizol 
(Invitrogen) and a Purelink Micro RNA isolation kit was used to isolate total RNA. 
Contaminating DNA was removed by on-column DNase treatment. The integrity and 
purity of the isolated RNA was determined using an Agilent Bioanalyzer. Samples used 
had an RNA integrity number of >7. 
 
 Herring       8 
qRT-PCR. 500ng of RNA was used in reverse transcription reactions (High Capacity 
RT-cDNA Kit, Life Technologies). Real time PCR was performed using Syber Green 
(Roche). For samples from human subjects levels of mRNA expression were 
normalized to expression of TATA binding protein (TBP) as an internal control and are 
expressed relative to the mean values seen in samples from control patients. For 
samples from mice levels of mRNA expression were normalized to expression of Hprt 
as an internal control and are expressed relative to the mean values seen in samples 
from control mice (either corn oil treated Foxf1ff Myh11creER(T2)+/-, Foxf2ff 
Myh11creER(T2)+/- or Foxf1/2ff Myh11creER(T2)+/- mice or tamoxifen treated  Foxf1ff, 
Foxf2ff or Foxf1/2ff mice, as indicated). Primers used for PCR are indicated in 
Supplemental Table 1. 
 
Smooth muscle-specific knockout of Foxf1 and Foxf2 in adult mice.  All mouse studies 
were performed in accordance with procedures approved by the Indiana University 
School of Medicine Institutional Animal Care and Use Committee.  
 
Foxf1ff and Foxf2ff mice, described previously23,24, were crossed with Myh11-creER(T2) 
mice27 to generate Foxf1ff Myh11creER(T2)+/-, Foxf2ff Myh11creER(T2)+/- or Foxf1/2ff 
Myh11creER(T2)+/- mice. In order to induce knockout of Foxf genes at 5-6 weeks of age 
these mice were treated with tamoxifen once a day for 5 days (100µl of 10mg mL-1 
tamoxifen in corn oil given IP). Control mice were either mice of the same genotype 
given corn oil injections instead of tamoxifen or were Foxf1ff, Foxf2ff of Foxf1ff/f2ff mice 
treated with tamoxifen. Only male mice were used for all experiments as the 
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Myh11creER(T2) transgene is on the Y chromosome. For some experiments we 
crossed the floxed mice onto myocdmyc-HA/myc-HA mice in which a myc-HA epitope tag 
was introduced into the carboxy-terminus of the endogenous myocardin using Crispr.28 
Ultimately this resulted in generation of Foxf1fff2ff Myocdmyc-HA/myc-HA Myh11cre ER(T2)-/+ 
that were used in experiments. The Myocdmyc-HA/myc-HA mice were generated by co-
injection of a guide RNA (acagcagugguaaacacccg), targeting oligonucleotide  
 (caacatcgattttctggatgttacagatcttaatctgaattcccctatggatctccacttacagcagtgggaacaaaaactca
tctcagaagaggatctgaattacccatacgatgttccagattacgcttgaacacccgaggtacaagagctacgagagctc
agtgggaattcaatggaggaaagcacgataccggaaa) and Cas9 protein (obtained from SAGE 
Labs – now Horizon Discovery) into fertilized oocytes obtained from C57BL/6J mice. 
Insertion of this sequence into the 3’ end of myocardin results in expression of 
myocardin with carboxyl-terminal myc and HA epitope tags (carboxyl-terminal amino 
acid sequence: LQQW-EQKLISEEDLNYPYDVPDYA*, myc and HA epitopes are 
underlined). Correctly targeted mice were identify by PCR and confirmed by direct DNA 
sequencing. Mice were outbred to C57BL/6J mice for 3 generations before homozygous 
Myocdmyc-HA/myc-HA and Foxf1fff2ffMyocdmyc-HA/myc-HA were generated. Myocdmyc-HA mice 
are available from JAX (Stock # 030703, C57BL/6J-Myocd<em1Bph>/J). 
 
Immunofluorescence imaging. For confocal imaging, mouse tissues (stomach body or 
aorta) were fixed in 4% paraformaldehyde for 2 hours on ice. Following fixation, tissues 
were washed in phosphate buffered saline for 3x 5 minutes and then cryoprotected by 
incubation in PBS containing 20% sucrose overnight at 4° before being frozen in OCT 
tissue freezing media (Tissue-Tech) on a bed of dry ice/2-methylbutane. Cryosections 
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(8µm) were cut and stored at -80°. For immuno-fluorescent staining cryosections were 
permeabilized in 0.2% triton in tris buffered saline (TBS) for 5 minutes, washed in TBS 
for 5 minutes them blocked in 5% donkey serum diluted in TBS at room temperature for 
1 hour. Blocked sections were incubated for 48 hours at 4° with primary antibodies to 
Foxf1 (1:400, Goat polyclonal antibody AF4798, 1:800, R&D Systems, Minneapolis, 
MN), Foxf2 (1:200, Sheep polyclonal antibody AF6988, R&D Systems, Minneapolis, 
MN), HA (1:100, Rabbit monoclonal antibody C29F4, Cell Signaling, Danvers, MA),  kit 
(Rabbit monoclonal antibody D13A2, Cell Signaling, Danvers, MA), PDGFRα (1:200, 
rabbit polyclonal antibody, 3164, Cell Signaling, Danvers, MA), or PGP9.5 (1:200, 
Rabbit polyclonal antibody A01398-40, Genscript, Piscataway, NJ) diluted in 5% donkey 
serum/TBS. Some sections were incubated without primary antibody as a negative 
control. Following washing in TBS, primary antibodies were detected by incubation with 
anti-goat, rabbit or sheep Alexa Fluor 647, Alexa Fluor 488 or Rhodamine-X (1:1,000, 
Jackson ImmunoResearch) as appropriate. For slides in which smooth muscle α-actin 
was visualized, Cy3 conjugated anti-smooth muscle α-actin antibody (1:250, Mouse 
monoclonal clone 1A4, #C6198 MilliporeSigma, Burlington, MA) was added along with 
the other secondary antibodies. After washing slides were mounted in Prolong Gold 
containing DAPI (Invitrogen) and visualized by confocal microscopy. Images shown are 
single confocal slices. 
 
Western blotting. For Western blotting protein lysates were generated by homogenizing 
frozen stomach antrum (in which the mucosa had been removed by careful dissection 
prior to freezing) in RIPA lysis buffer (1%NP-40, 1% sodium deoxycholate, 0.1% SDS, 
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0.15M NaCl, 0.01M sodium phosphate pH7.2, 2mM EDTA, 50mM NaFl) in a glass 
homogenizer on ice. Insoluble material was removed by a brief centrifugation and 
protein concentrations of the lysates determined using a BCA assay (Biorad). Either 5 
or 25µg aliquots of lysates were separated on 7.5% acrylamide gels. Proteins were 
transferred to nitrocellulose membranes overnight at 70mA in a buffer containing 
0.192M glycine, 0.25M Tris, 0.05%SDS, 20% methanol, following transfer, blots were 
stained with Ponceau S to visualized the transferred proteins then blocked in 5% BSA 
dissolved in 10mM Tris ph7.5, 150mM NaCl, 0.05% tween 20 (TBST). Blots were 
incubated with primary antibodies in the same solution overnight at 4°C. Primary 
antibodies used for western blotting were against; myh11 (SM1 and SM2 isoforms),29 
HA (NB600-363, 1µg/ml, Novus Biologicals, Littleton, CO), calponin (13938-1-AP, 0.2µg 
mL-1, Proteintech), SM22α (1:10,000, rabbit polyclonal antibody raised against the 
peptide CGPDVGRPDRGRLGFQVW (residues 38-55 of mouse, rat and human SM22α, 
Proteintech), ACTA2 (Clone 1A4, 1:10000, Sigma), vinculin (Clone VIN11-A5, 1:10000, 
Sigma), gamma1 tubulin (Clone GTU-88, 1:1000, Millipore-Sigma). Following washing 
with TBST (3x 5minutes) blots were incubated with the appropriate horse radish 
peroxidase conjugated secondary antibodies diluted in TBST containing 2% gelatin at  
room temperature for 45 minutes. Protein bands were visualized on a G-box imager 
(Syngene) following incubation with ECL Western blotting substrate (Pierce). 
 
Liquid gastric emptying assays. 
Prior to liquid gastric emptying assays mice were deprived of food and bedding for 
about 18 hours. Two hours following removal of water from the mice they were given an 
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oral gavage of 100µl of Rhodamine dextran in methylcellulose (2.5mg mL-1 Rhodamine 
B dextran 70K dissolved in 1% methylcellulose). 15 minutes following the gavage the 
mice were euthanized by cervical dislocation and the esophagus, duodenum and ileum 
quickly clamped. The stomach and small intestine were then removed from the mouse. 
The stomach was placed in 4mL of saline and the small intestine was divided into 8 
equal length portions and each portion added to a tube containing 4mL of saline. 
Stomach and intestinal segments were homogenized using a polytron (Kineticore), 
samples were clarified by centrifugation (13,000g for 5 minutes). Rhodamine B was 
detected in 100µL aliquots of the lysates using a fluorescence plate reader (579nm 
excitation, 590nm emission.) % gastric emptying  = [sum of all fluorescence – stomach 
fluorescence] / all fluorescence x100 
 
Statistical analysis Significant differences between the means values of the 
gastroparesis and control patients or wild type and knockout mice were determined 
using a two-tailed, Welch corrected student T-test in order to account for potential 
differences in the variance in each group. P values <0.05 were considered significant. 
Experiments which compared expression between more than two groups used a one-
way Anova analysis to determine statistical significance (Kruskal Wallis test with a 
Dunn’s Multiple Comparison post test). 
 
Results 
FOXF expression is decreased in human patients with gastroparesis. Expression 
of FOXF1 and FOXF2 mRNA was measured by qRT-PCR in the isolated stomach 
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muscularis obtained from full thickness biopsies of control patients with no symptoms of 
gastroparesis and from patients with gastroparesis. Two groups of control patients were 
used. The first group included 14 patients undergoing bariatric weight loss surgery, 5 
patients from sleeve gastrectomy and 9 patients from Roux-en-Y bypass surgery.  None 
of these 14 controls subjects had diabetes (normal HbA1c < 1 month prior to surgery) 
(Figure 1A). The clinical description of these patients was described previously.16 The 
second group included 11 patients undergoing bariatric weight loss surgery that had 
diabetes. (Figure 1B). We also analyzed samples from two groups of patients with 
gastroparesis one group with no diabetes (16 patients with idiopathic gastroparesis 
described previously,16 Figure 1A) and one group in which the patients also had 
diabetes (9 patients with diabetic gastroparesis, Figure 1B). This analysis revealed that 
FOXF1 and FOXF2 mRNA levels were significantly decreased in the patients with 
idiopathic gastroparesis (Figure 1A) and FOXF1 mRNA was also significantly 
decreased in the patients with diabetic gastroparesis (Figure 1B).  
 
Knockout of Foxf1 and Foxf2 from adult gastric smooth muscle cells. In order to 
determine if loss of FOXF1 and/or FOXF2 may be contributing to the impaired gastric 
motility seen in human patients with gastroparesis we generated a mouse model in 
which Foxf1 and/or Foxf2 were specifically ablated in adult smooth muscle cells. To 
generate these mice the previously described Foxf1 and Foxf2 floxed mice23,24 were 
crossed with mice expressing a tamoxifen regulated cre recombinase driven by the 
smooth muscle myosin heavy chain (Myh11) promoter (Myh11creER(T2)27, as 
described in ‘Methods’. The efficacy of the knockout of Foxf1 and Foxf2 proteins was 
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determined by qRT-PCR and immunohistological analysis of cryosections cut from the 
stomach body of tamoxifen treated male Foxf1fff2ff Myh11creER(T2)-/+ mice compared to 
control mice either of the same genotype treated with corn oil or from Foxf1fff2ff mice 
treated with tamoxifen (Figures 2 and 3). Surprisingly we observed a significant 
decrease in Foxf1 and Foxf2 expression in Foxf1fff2ff Myh11creER(T2)-/+ mice treated 
with corn oil, suggesting that the creER(T2) transgene is at least partially active in the 
absence of tamoxifen (Figure 2A). To further examine this possibility we visualized the 
activity of the cre recombinase by crossing the Myh11creER(T2) mice with  a cre-
dependent mTmG reporter mouse as described previously.30 Fluorescence imaging of 
corn oil (CO) or tamoxifen (TAM) treated Myh11creER(T2)-/+ mTmG+/- mice revealed 
cre-dependent expression of the mEGFP reporter uniformly in the circular muscle layer 
(CM) of stomach and in the media of the aorta upon tamoxifen treatment. However, 
patchy cre-dependent expression of the mEGFP was also seen in stomach circular 
muscle of corn oil treated mice, although the aorta remained mEGFP negative and 
mTomato positive. The partial loss of Foxf1 and Foxf2 in the corn oil treated Foxf1fff2ff 
Myh11creER(T2)-/+ mice was further confirmed by immunofluorescence localization of 
the Foxf proteins (Figure 3). This analysis further confirmed the effective deletion of 
Foxf1 and Foxf2 from gastric SMCs in tamoxifen treated Foxf1fff2ff Myh11creER(T2)-/+ 
mice (Figure 3). Both Foxf1 and Foxf2 co-localized in gastric SMCs of control mice 
(Figure 3 and Supplemental data figure 1). The residual Foxf1 and to a lesser extent 
Foxf2 mRNA expression detected in the gastric antrum muscularis of knockout mice 
(Figure 2A), appears to result from Foxf expression in other cell types (Figure 3). In 
support of this, Foxf1 and Foxf2 expression was also detectable in kit positive interstitial 
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cells of Cajal (ICC) within the gastric muscularis, and this expression was not altered 
following tamoxifen treatment of Foxf1fff2ff Myh11creER(T2)-/+ mice (Figure 4). Lower 
levels of Foxf1 and Foxf2 expression were also detectable in PDGFRα positive 
fibroblasts (Supplemental data figure 2) and in submucosal and mucosal fibroblasts, 
although neural ganglia did not express detectable levels of Foxf1 or Foxf2 
(Supplemental data figure 2). 
 
Ablation of Foxf1 and Foxf2 from adult mouse gastric smooth muscle cells 
results in impaired liquid gastric emptying. To determine if loss of FOXF1 or FOXF2 
in humans could be contributing to impaired gastric emptying in gastroparesis patients 
we examined the rate of liquid gastric emptying in mice lacking Foxf1, Foxf2 or both 
proteins. This analysis revealed that mice lacking Foxf1 and Foxf2 had significantly 
impaired liquid gastric emptying compared to control mice (Figure 5). Neither single 
knockout or double heterozygous mice exhibited this phenotype and all control mice 
examined had similar liquid gastric emptying rates (Figure 5).  
 
Foxf1 and Foxf2 double knockout mice exhibit marked decreases in mRNAs 
encoding contractile proteins. qRT-PCR analysis of stomach antrum obtained from 
Foxf1/2 double knockout mice revealed a significant decrease in mRNAs encoding 
contractile proteins such as Myh11, Acta2, calponin and SM22α (Figure 6). This was 
accompanied by decrease in mRNAs encoding myocardin and SRF, two transcriptional 
activators that are known to be required for the expression of these smooth muscle 
proteins. We also observed a small but significant decrease of Kitlg mRNA and a 
 Herring       16 
marked decrease in BMP4 mRNA (Figure 6). A significant decrease in myocardin 
mRNAs was also observed in the single Foxf2 knockout mice whereas in the single 
Foxf1 knockout mice we observed significant decreases in expression of calponin and 
myocardin (Figure 6).  
 
SRF and myocardin proteins are decreased in Foxf1/2 double knockout mice. To 
determine if the transcriptional changes that we observed in figure 6 also reflect 
changes in protein levels we performed a Western blot analysis. As there are no 
commercially available antibodies that can reliably detect endogenous myocardin 
protein we first generated a knockin mouse in which we knocked in myc-HA epitope 
tags into the 3’ end of the endogenous myocd gene (Methods). This allowed us to use 
antibodies to HA to detect the endogenous myocardin protein. The MyocardinHA/HA mice 
were crossed into the Foxf1ff2ff mice so that the knockout mice had one or both alleles 
of myocd tagged with HA. Western blot analysis revealed a significant decrease in 
myocardin, SRF, myh11 (SM1 and SM2 isoforms), calponin and SM22α protein levels 
in the stomach antrum of Foxf1/2 double knockout mice  (Figure 7). We also observed a 
decrease in the SMC selective meta-vinculin. Confocal microscopy also revealed 
decreased myocardin-HA expression in gastric SMCs of the Foxf1/2 double knockout 
mice (Supplemental data figure 3).  
 
Discussion 
Results from our studies show that FOXF1 and FOXF2 mRNA is decreased in the 
stomach of human patients with gastroparesis and that loss of Foxf1 and Foxf2 in adult 
 Herring       17 
mice is sufficient to result in delayed liquid gastric emptying. Although it is unlikely that 
the observed decreased expression of FOXF1 and FOXF2 in humans is in itself 
sufficient to cause gastroparesis our findings from knockout mice suggest that the 
decreased FOXF expression may be contributing to the pathogenesis of gastroparesis 
in humans. This proposal must, however, be interpreted within the limitations of our 
study. Firstly, we have not been able to confirm that the decreased FOXF1 and FOXF2 
mRNA expression in humans is mirrored by decreased FOXF protein expression, as we 
have not been able to detect these proteins by Western blotting using our antibodies. 
Secondly, although the Foxf1/f2 double knockout mice had impaired liquid gastric 
emptying and decreased expression of smooth muscle contractile proteins, we have not 
directly measured the contractility of the stomach muscle in these mice. Although, as we 
have previously shown that smooth muscle-specific knockout of Foxf1 during embryonic 
development results in decreased contractile protein expression and impaired intestinal 
contractility, it seems reasonable to suggest that stomach contractility may be impaired 
in the adult smooth muscle-specific Foxf1/f2 double knockout mice described in the 
current study.24 Finally, although gastroparesis is more prevalent in females than males 
in humans we have not been able to access the effects of Foxf1/f2 knockout in female 
mice as the Myh11 creER(T2) transgene used in our study is located on the Y 
chromosome.27  
 
In the samples obtained from humans with gastroparesis, there was reduced but not 
abolished expression of FOXF1 and FOXF2 mRNA (Figure 1). However, in mice we 
only observed impaired gastric emptying in the homozygous knockout mice, neither 
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heterozygous mice or corn oil treated Foxf1fff2ff Myh11creER(T2)-/+ mice that had~50% 
reduction in Foxf1 and Foxf2 mRNA levels exhibited any detectable defects in liquid 
gastric emptying (Figures 2,5). Moreover both these latter two groups of mice had 
similar rates of liquid gastric emptying compared to control tamoxifen treated Foxf1fff2ff  
mice (Figure 5). However, it is important to note that in mice we measured gastric 
emptying of a liquid meal whereas in humans a solid meal is used for gastric emptying 
studies. It is possible that this difference in methodology is affecting the sensitivity of our 
detection of delayed emptying in mice. Alternatively, our findings may suggest that 
either humans are more sensitive to decreased FOXF expression, or more likely that 
there are other changes that occur in the human subjects that act together with 
decreased smooth muscle FOXF1/2 levels leading to impaired gastric emptying. 
Consistent with this latter possibility, it has recently been shown that FOXF1 plays a 
critical role in ICC, which would not be predicted to be affected in our smooth muscle-
specific Foxf1/2 knockout mice.31 Furthermore, both Foxf1 and Foxf2 are readily 
detectable in ICC of both control and smFoxf1/2 knockout mice (Figure 4). In the 
smFoxf1/2 knockout mice we did observe statistically significant decrease in Kitlg 
mRNA, although there was no change in Kit or Ano1(Anoctamin 1) mRNA, two 
established markers of ICC.32 The decreased Kitlg expression would be consistent with 
previous studies that showed decreased Kitlg expression in a rodent diabetic 
gastroparesis model.33 However, the lack of change in the mRNAs encoding ICC 
markers is not consistent with the proposal that the decreased Kitlg results in decreased 
Kit signaling in ICC, leading to their death.33 The role of ICC loss or dysfunction in 
human gastroparesis is also not fully resolved, although several immunohistological 
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studies have suggested that gastroparesis is associated with a loss of ICC,14,33-35 in a 
recent study we did not observe any detectable changes in mRNA levels of ICC 
markers KIT or ANO1 in patients with idiopathic gastroparesis.16 Whether these results 
reflect differences between protein and mRNA expression or other differences in the 
methodologies employed remains to be determined. 
 
Previously we showed that Foxf2 knockout from SMCs during development results in 
elevated PDGFb expression and increased proliferation of SMCs in the longitudinal 
layer of the GI tract and an expansion of the myenteric plexus.23 Although we did not 
observe any changes in PDGFb expression when Foxf2 was knocked out from adult 
smooth muscle, we did see a small but significant increase in the pan neural marker, 
nestin in the Foxf2 KO mice, suggesting that there may be some neural expansion in 
these mice (Figure 6). Surprisingly, increased nestin expression was also seen in the 
Foxf1 KO mice yet not in the double knockout mice (Figure 6). The meaning of these 
findings are unclear. Although the lack of change in the double knockout mice suggest 
that the increased nestin expression in the single knockout mice is not simply a 
compensatory effect due to potentially impaired muscle activity, as this would be 
expected to be worse in the double knockout mice.  
 
One surprising technical finding from our study was the tamoxifen independent activity 
of the Myh11creER(T2) transgene in gastric SMCs (Figure 2). This transgenic mouse 
line has been used extensively to achieve regulated smooth muscle-specific ablation of 
genes and most of these previous studies have shown tight tamoxifen dependent 
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regulation of the cre recombinase activity.27,30,36 Our current findings suggest that 
although cre activity appears to be completely tamoxifen dependent in vascular smooth 
muscle there is a significant tamoxifen independent cre activity in GI smooth muscle 
(Figure 2). This highlights the importance of utilizing several different mouse control 
lines to both monitor potential effects of tamoxifen itself and to evaluate possible 
hypomorphic effects of partial gene deletion from GI smooth muscle in the absence of 
tamoxifen. Future studies utilizing this cre transgene should thus be interpreted with 
caution if they do not address these issues.  
 
Early studies on Foxf proteins showed that they are part of a signaling pathway through 
which sonic hedgehog (shh) regulates patterning of the GI tract during embryonic 
development.37,38 In this pathway, shh released from epithelial cells stimulates the 
transcription of Foxf1 in adjacent mesodermal cells. In turn Foxf1 drives transcription of 
BMP4 which is released from the developing mesodermal cells and then feeds back to 
the GI epithelial cells to regulate their proliferation. Consistent, with these observations 
we have previously shown that deletion of Foxf1 from SMCs during development leads 
to impaired BMP4 expression. In the current study, we show that Foxf1 and Foxf2 
appear to play partly redundant roles in regulating BMP4 expression in that we only 
observed a significant decrease in BMP4 mRNA expression in the double knockout 
mice (Figure 6). Examining the effects of the decreased BMP4 on the mucosa of adult 
mouse stomach will be an interesting avenue for future investigation. 
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In summary, we have shown that expression of mRNA encoding FOXF1 and FOXF2 is 
decreased in human subjects with gastroparesis and that loss of both these proteins 
from adult smooth muscle in mice is sufficient to impair liquid gastric emptying. These 
findings together with our previous studies showing Foxf regulation of SRF/myocardin 
transcriptional complexes23,24 and altered transcriptional activity of contractile protein 
genes in the stomach of patients with gastroparesis16 suggest that SRF containing 
transcriptional complexes may play a central role in pathological changes that lead to 
gastroparesis.  
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Figure Legends 
 
Figure 1. Expression of FOXF1 and FOXF2 in stomach muscle from human 
subjects with gastroparesis. Total RNA was isolated from the muscle layer of 
biopsies obtained from 14 control subjects and 16 subjects with idiopathic 
gastroparesis, with no diabetes (A) or 11 control subjects with diabetes and 9 subjects 
with diabetic gastroparesis (B). qRT-PCR was used to measure the expression of each 
of the mRNAs indicated. Data presented were normalized to an internal control 
encoding TBP and are expressed relative to levels in the respective control subjects. 
Relative expression =2-∆∆Ct,  where ∆∆Ct = (CtGastroparesis-CtTBP) – (Ctcontrol-CtTBP). Each 
circle represents an individual subject with the control subjects represented as open 
 Herring       25 
circles and the gastroparesis subjects as closed circles. The mean±SEM are also 
indicated. Student T-tests were used to identify statistical significance.  P-values are 
indicated. 
 
Figure 2. Myh11creER(T2) exhibits tamoxifen independent activity in the stomach. 
A. qRT-PCR analysis of Foxf1 and Foxf2 expression in stomach antrum isolated from 
the indicated mouse strains four weeks after treatment with tamoxifen or corn oil (1mg 
(100µl) daily for 5 days). Data presented were normalized to an internal control 
encoding Hprt and are expressed relative to levels in the Foxf1fff2ff mice treated with 
tamoxifen(control). * indicates significant differences (P<0.05) from Foxf1fff2ff + TAM 
mice determined by one-way Anova analysis. Relative expression =2-∆∆Ct,  where ∆∆Ct 
= (Cttest-CtHprt) – (Ct control-CtHprt). An additional housekeeping gene (RPLPO, Ribosomal 
protein lateral stalk subunit P0) was analyzed as a further control. B. To visualize the 
activity of the cre recombinase encoded by the smHCcreER(T2) transgene we crossed 
these mice to the mTmG reporter mouse as described previously.30 Fluorescence 
imaging of corn oil (CO) or tamoxifen (TAM) treated Myh11creER(T2)-/+ mTmG mice 
revealed cre-dependent expression of the mEGFP reporter uniformly in the circular 
muscle layer (CM) of stomach body and in the media of the aorta upon tamoxifen 
treatment. However, patchy cre-dependent expression of the mEGFP was also seen in 
stomach body circular muscle of corn oil treated mice, although the aorta remained 
mTomato positive. White arrows indicate patches of mEGFP positive smooth muscle 
cells in the corn oil treated mice.  
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Figure 3. Foxf proteins are efficiently knocked out of smooth muscle cells in 
Foxf1fff2ff Myh11creER(T2)-/+ mice treated with tamoxifen. Immunofluorescence 
staining of Foxf1 (white nuclei), Foxf2 (green nuclei) and ACTA2 (red) in stomach body 
of tamoxifen (TAM) treated Foxf1/2ff mice and Foxf1ff Myh11creER(T2)+/- mice treated 
with corn oil (CO) or tamoxifen (TAM). Mice were treated with tamoxifen or corn oil at 5 
weeks of age, once a day for 5 days. Four weeks later tissues were harvested and 
processed for immunofluorescence microscopy as described in ‘Methods’. White arrows 
indicate Foxf1 and Foxf2 positive smooth muscle cells. Yellow arrows indicate other 
cells that are Foxf1 and Foxf2 positive (likely ICCs).  
 
Figure 4. Foxf proteins are efficiently knocked out of smooth muscle cells but 
remain expressed in ICC and mucosal fibroblasts. Immunofluorescence staining of 
Foxf1 (red), Foxf2 (green), Kit (cyan) and nuclei (blue) in stomach body of tamoxifen 
treated, Foxf1ff/2ff control mice and Foxf1ff/2ff Myh11creER(T2)+/- mice (Foxf1f2 smKO). 
Mice were treated with tamoxifen at 5 weeks of age, once a day for 5 days. Four weeks 
later tissues were harvested and processed for immunofluorescence microscopy as 
described in ‘Methods’. Yellow arrows indicate Foxf1 and Foxf2 positive ICCs (Kit 
positive). CM- circular muscle, MG- myenteric ganglia. 
 
Figure 5. Knockout of Foxf1 and Foxf2 results in delayed liquid gastric emptying. 
Foxf1ff Myh11creER(T2)+/- (smFoxf1 KO), Foxf2ff Myh11creER(T2)+/- (smFoxf2 KO), 
Foxf1f+/2f+ Myh11creER(T2)+/- (smFoxf1/2 Het) or Foxf1ff/2ff Myh11creER(T2)+/- 
(smFoxf1/2 KO) mice were treated with corn oil (CO) or tamoxifen (TAM) at 5 weeks of 
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age, once a day for 5 days. The smFoxF1/2 KO MyocdHA/HA graph shows data from 
Foxf1ff/2ff Myocd HA/HA mice (grey bar) and Foxf1ff/2ff Myh11creER(T2)+/- MyocdHA/HA 
mice (black bar) both treated with tamoxifen. Four weeks later liquid gastric emptying 
was assayed following oral gavage of rhodamine dextran. The mean±SD percent 
gastric emptying is shown. The numbers in brackets represent the number of mice in 
each group. * indicates significant difference between CO and Tam treated mice as 
determined by T test. No significant differences were observed between the gastric 
emptying rates of control mice (One-way Anova). 
 
Figure 6. Knockout of Foxf1 and Foxf2 from adult mouse smooth muscle results 
in decreased expression of mRNAs encoding smooth muscle contractile proteins. 
qRT-PCR analysis of mRNA expression in antrum smooth muscle from knockout mice. 
Analysis was performed as described in figure 2, mRNA levels in each of the knockout 
mice were expressed relative to a common group of tamoxifen treated Foxf1ff/f2ff, 
control mice (n=15 ). Foxf1ff Myh11creER(T2)+/- (F1KO) (n=8) , Foxf2ff 
Myh11creER(T2)+/- (F2KO) (n=6) or Foxf1ff/2ff Myh11creER(T2)+/- (F12KO) (n=12) were 
treated with tamoxifen (TAM) as described in figure 2. Data shown are mean±SD * 
P<0.05 determined by one-way Anova analysis. 
 
Figure 7. Knockout of Foxf1 and Foxf2 from adult mouse smooth muscle results 
in decreased expression of myocardin and SRF proteins. A. Western blot analysis 
of protein expression in antrum smooth muscle from control Foxf1ff2ff MyocdHA/HA mice, 
smF12KO MyocdHA/HA mice and Foxf1ff/2ff control mice. All mice were treated with 
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tamoxifen as described in methods. 1µg (SM1, SM2, vinculin, calponin, SM22α, 
GAPDH) or 25µg (HA, SRF, GAPDH, γ-tubulin) of protein were separated on 7.5% 
(SM1, SM2, HA, SRF, vinculin, ACTA2) and 15% (calponin, SM22α, GAPDH) 
polyacrylamide gels and analyzed by western blotting. Molecular mass markers are 
indicated to the left of the blots (kDa). B. Quantitation of the levels of protein expression 
observed in the blots in panel A. Expression levels were normalized relative to γ-tubulin. 
P-values from student T-tests between F1ffF2ff MyocdHA/HA and smF12KO MyocdHA/HA 
samples are indicated. 
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